Relief Therapeutics Holding SA (RLFTF)
- Previous Close
5.00 - Open
6.19 - Bid 6.05 x 40000
- Ask 6.42 x 40000
- Day's Range
6.19 - 6.19 - 52 Week Range
1.10 - 7.45 - Volume
143 - Avg. Volume
2,681 - Market Cap (intraday)
79.546M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-4.22 - Earnings Date Aug 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Relief Therapeutics Holding SA, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting; OLPRUVA, a sodium phenylbutyrate for the treatment of urea cycle disorders, and maple syrup urine disease; and PKU GOLIKE for for the dietary management of phenylketonuria. It also develops TYR GOLIKE, that has completed Phase III clinical trial to treat Tyrosinemia; and RLF-100, a synthetic form of vasoactive intestinal peptide (VIP), that is in Phase II clinical trial for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19 related ARDS and in preclinical trial to treat pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis. In addition, the company also develops HCU GOLIKE, which is in Phase I clinical trial for the treatment of Homocystinuria; and RLF-TD011, a hypochlorous acid topical sprayable solution, that is in Phase I clinical trial to treat wound colonization, reduce local inflammation, alleviate symptoms, and hasten wound healing in epidermolysis bullosa. Further, it is developing RLF-OD32, which is in Phase I clinical trial for the treatment of patients with phenylketonuria; and. Relief Therapeutics Holding SA was founded in 2013 and is based in Geneva, Switzerland.
www.relieftherapeutics.comRecent News: RLFTF
View MorePerformance Overview: RLFTF
Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RLFTF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RLFTF
View MoreValuation Measures
Market Cap
82.89M
Enterprise Value
73.25M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.04
Price/Book (mrq)
1.41
Enterprise Value/Revenue
7.35
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
-4.22
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--